Regenxbio (RGNX) Total Current Liabilities (2014 - 2026)
Regenxbio (RGNX) posted quarterly Total Current Liabilities of $118.1 million for Q4 2025, up 14.44% year-over-year from $103.2 million in Q4 2024, and down 5.2% quarter-over-quarter from $124.6 million in Q3 2025.
Regenxbio (RGNX) Total Current Liabilities (2014 - 2026) Analysis & Trends
Regenxbio's Total Current Liabilities history runs 12 years deep, the most recent figure standing at $118.1 million for Q4 2025.
- In Q4 2025, Total Current Liabilities rose 14.44% year-over-year to $118.1 million; the TTM figure through Dec 2025 stood at $118.1 million (up 14.44% YoY), while the FY2025 annual figure was $118.1 million, up 14.44% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $118.1 million, down from $124.6 million in the prior quarter.
- The five-year high for Total Current Liabilities was $130.5 million in Q4 2021, with the low at $84.0 million in Q1 2021.
- The 5-year median for Total Current Liabilities is $116.2 million (2022), against an average of $113.6 million.
- The sharpest annual moves came in 2021 and 2024: Total Current Liabilities soared 164.12% in 2021, then dropped 20.79% in 2024.
- Regenxbio's Total Current Liabilities stood at $130.5 million in 2021, then declined by 0.03% to $130.4 million in 2022, then retreated by 0.12% to $130.3 million in 2023, then slipped by 20.79% to $103.2 million in 2024, then gained by 14.44% to $118.1 million in 2025.
- Business Quant data shows RGNX's Total Current Liabilities at $118.1 million in Q4 2025, $124.6 million in Q3 2025, and $119.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | 82.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 82.62 Mn |
| Dec 31, 2025 | 118.10 Mn |
| Sep 30, 2025 | 124.57 Mn |
| Jun 30, 2025 | 119.54 Mn |
| Mar 31, 2025 | 106.73 Mn |
| Dec 31, 2024 | 103.19 Mn |
| Sep 30, 2024 | 102.73 Mn |
| Jun 30, 2024 | 98.27 Mn |
| Mar 31, 2024 | 110.18 Mn |
| Dec 31, 2023 | 130.27 Mn |
| Sep 30, 2023 | 127.35 Mn |
| Jun 30, 2023 | 117.89 Mn |
| Mar 31, 2023 | 112.33 Mn |
| Dec 31, 2022 | 130.43 Mn |
| Sep 30, 2022 | 123.55 Mn |
| Jun 30, 2022 | 114.56 Mn |
| Mar 31, 2022 | 119.94 Mn |
| Dec 31, 2021 | 130.47 Mn |
| Sep 30, 2021 | 106.77 Mn |
| Jun 30, 2021 | 91.55 Mn |